AB122

Phase 1Small molecule

Taiho Pharmaceutical Co., Ltd.

AB122 is one of 17 small molecule programs targeting Advanced or Metastatic Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Metastatic Solid TumorRecruiting

Advanced or Metastatic Solid TumorPhase 1

Recruiting

Competition

Competitive Landscape

21 competitors in Advanced or Metastatic Solid Tumor

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

1 2

Cyramza

Eli Lilly

Phase 1

1 3

Avastin

Roche

Phase 1

1 4

Abraxane

Bristol-Myers Squibb

Phase 1

1 5

Gemzar

Johnson & Johnson

Phase 1

1 6

Trodelvy

Gilead

Phase 1

1 7

Adrucil

EElorac, Inc.

Phase 1

1 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 9

Paraplatin

AAvyxa

Phase 1

1 10

Saruparib

AstraZeneca

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Advanced or Metastatic Solid Tumor

NCT04999761

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumor1 trial

Platform Study of AB122 Based Treatments in Patients With Advanced Solid Tumors

Recruiting· Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.·Phase 1·NCT04999761·917 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AB122. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AB122 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AB122. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taiho Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Taiho Pharmaceutical Co., Ltd.

AB122

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Advanced or Metastatic Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News